In addition, miR-22 was also reported to affect lipogenesis and production of pro-inflammatory cytokines through silencing SIRT1 transcription,405 suggesting that miR-22 inhibition may have therapeutic potential for harnessing NAFLD and obesity by manipulating the metabolic gene-expression landscape. The gene discussed is SIRT1; the disease is metabolic dysfunction-associated steatotic liver disease.